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aPharmacy Department, National and Kapodistrian University of Athens, Athens, Greece; bFaculty of Social and Political Sciences, University
of Peloponnese, Corinth, Greece
ABSTRACT
Background: Clinical practice guidelines for the treatment of idiopathic pulmonary fibrosis (IPF) cur-
rently recommend pirfenidone and nintedanib. However, there is a lack of evidence from head-to-
head comparisons.
Objectives: To perform a systematic review and network meta-analysis (NMA) to access the efficacy
and tolerability of two new treatments for IPF, pirfenidone and nintedanib.
Methods: Randomized controlled trials (RCTs) selection (CENTRAL, MEDLINE, Embase), data extraction,
risk of bias analysis, and GRADE assessment were carried out by two authors separately. Direct esti-
mates were calculated using standard pairwise meta-analysis. A Bayesian mixed treatment comparison
approach for NMA estimates, with 95% confidence intervals (CI), was used to compare the treatments,
calculating odds ratios (OR) and number needed to treat (NNTB) or harm (NNTH).
Results: The NMA on 10 randomized controlled trials showed that each drug had a positive effect on
percentage of forced vital capacity (FVC) decline 10% (pirfenidone OR¼ 0.54 [95% CI¼ 0.37–0.80],
NNTB¼ 9 [95% CI¼ 7–22]; nintedanib OR¼ 0.59 [95% CI¼ 0.41–0.84], NNTB¼ 9 [95% CI¼ 6–23]), but
no significant differences were noted when comparing pirfenidone and nintedanib with respect to
acute exacerbations, mortality, and serious adverse events (FVC decline OR¼ 0.91 [95% CI¼ 0.45–2.03])
or dropouts (OR¼ 0.75 [95% CI¼ 0.33–1.27]). Nintedanib showed an effect on dropouts, OR¼ 1.61
(1.13–2.28) and NNTH¼ 14 (8–61).
Conclusions: Based on RCTs of 12month duration in patients with IPF, a positive effect on FVC
decline was noted for both treatments and on dropouts for nintedanib, but no significant differences
were noted between treatments.
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Introduction
Idiopathic pulmonary fibrosis is the most common type of
idiopathic interstitial pneumonia, and its incidence and
prevalence indicate that it is a disease which heavily impacts
healthcare systems globally. It is a chronic progressive dis-
ease that primarily occurs in middle-aged and older adults
and accounts for 20–30% of interstitial lung diseases1.
In Europe, IPF prevalence has been reported to range
from 1.25–23.4 cases per 100,000 population, and the annual
incidence is between 0.22 and 7.4 per 100,000 population2,
but both increase with age, are higher among males, and
appear to be on the increase in recent years. A recent epi-
demiological study in northern Italy estimated the mean
annual incidence rate to be 2.3 using narrow case definitions,
while the estimated annual prevalence rate was 12.6 per
100,000 person-years3.
Although its cause remains unknown, multiple genetic
and environmental factors may play a role in the
pathogenesis and progression of pulmonary fibrosis, includ-
ing infectious agents (bacterial and viral pathogens), particu-
late inhalation (cigarette smoking, dusty environments), and
several occupational factors, such as farming, livestock, hair-
dressing, metal dust, raising birds, stone cutting/polishing,
and vegetable dust/animal dust4,5.
Patients typically> 45 years old present with non-specific
symptoms of exertion dyspnea with or without dry cough,
bilateral inspiratory crackles, and sometimes finger clubbing.
Occasionally, patients will present acute symptoms, with
days to weeks of respiratory worsening, often accompanied
by fever and influenza-like symptoms6.
The 2013 clinical guidelines produced by the National
Institute for Health and Clinical Excellence (NICE)6 recognize
the fact that the initial assessment of individuals with IPF
needs to be improved, to reduce the risk of delays in diagno-
sis and initiation of treatment, including monitoring and best
supportive care (BSC). The assessment must include clinical
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features, imaging (High-resolution CT, histopathology, and
spirometry)7, and should be multidisciplinary at each stage
of the diagnostic care pathway to include a consultant
respiratory physician, consultant radiologist, and ILD special-
ist nurse. This multidisciplinary approach is considered the
diagnostic gold standard, although a few patients remain
unclassifiable8. The clinical course of IPF may be variable and
unpredictable and may be interspersed with acute exacerba-
tions. The median survival time from diagnosis is 2–4 years9.
Three “pillars” of care are described for IPF: disease-cen-
tered management, symptom-centered management, and
education and self-management10. Best supportive, or pallia-
tive, care is a proactive approach to symptomatic treatment
and in IPF may include oxygen therapy, pulmonary rehabili-
tation, opiates, antireflux therapy, the withdrawal of steroids,
and other immunosuppressants, early recognition of terminal
decline, and liaison with palliative care specialists11. Also, the
NICE 2013 guideline suggests that ambulatory oxygen should
be considered if a patient with IPF has breathlessness on
exertion, and benzodiazepines and/or opioid therapy if a
patient has breathlessness at rest6.
Until recently, no intervention, other than lung transplant-
ation, has demonstrated an enhanced survival in patients
with IPF12, but a few novel agents have demonstrated a
decreased rate of disease progression as measured by forced
vital capacity (FVC)13,14. Two of these novel agents,
Pirfenidone, an orally bioavailable synthetic molecule with
antifibrotic and anti-inflammatory properties, and Nintedanib,
an intracellular inhibitor of tyrosine kinases that received
orphan status from the European Medicines Agency in 2013,
have both marketing authorization for use in IPF in Europe.
In the absence of head to head trials comparing these treat-
ment regimens, systematic reviews, meta-analyses (MA), and
network meta-analyses (NMA) are the suggested tools for
their further exploration for the first line treatment of IPF.
Recently, several NMAs have investigated the newer treat-
ments for IPF15–19. However, the aim of the present study
was to perform a systematic review and network meta-ana-
lysis (NMA), using FVC> 10% decline, acute exacerbations,
dropouts, mortality and serious adverse events as endpoints,
in order to access the efficacy and safety of pirfenidone and
nintedanib to treat patients with IPF and, thus, generate a
clinically useful ranking of these treatments.
Methods
Criteria for considering studies for inclusion
Parallel group Randomized Controlled Trials (RCTs) of pirfeni-
done or nintedanib for patients with IPF were included.
Eligible studies were Phase II and III randomized controlled
trials (RCTs), published in English. Quasi-randomized and
cross-over trials were excluded. IPF was defined by the 2015
criteria20. Studies that included patients with other con-
founding respiratory conditions and idiopathic interstitial
idiopathic pneumonia other than IPF were excluded.
Search methods for the identification of clinical trials
A systematic review based on a protocol developed a priori
up to September 2017 was performed. The following data-
bases (MEDLINE, EMBASE, the Cochrane Library, and
PubMed), conference proceedings, and previous systematic
reviews were searched up to May 2017.
Types of participants
Individuals aged 18 years with suspected or diagnosed IPF.
Types of interventions
Pirfenidone or nintedanib compared with one of the other
interventions or placebo. Study arms investigating the
approved doses of pirfenidone and nintedanib (pirfenidone
1,800 or 2,403mg/day and nintedanib 300mg/day)
were included.
Types of outcomes
Primary outcomes included the number of participants with
an FVC decrease> 10%, acute exacerbations, dropouts, ser-
ious adverse events, and all-cause death. A> 10% decrease
in FVC was considered clinically meaningful, even though a
decrease of as little of 2–6% for %FVC has been estimated to
be the minimal clinical requirement21. This converts the con-
tinuous %FVC to a binary event. The relative ranking of the
competing interventions was determined according to the
above-mentioned primary outcomes. Other outcomes
included the number of Serious Adverse Events.
Data collection and analysis
A brief RCT search strategy (BRSS), consisting of a search of
CENTRAL, and then for variants of the word random across
all fields (random$.af.) in MEDLINE and EMBASE, was devised
and run. The search strategy was designed to search for IPF
and RCTs, pirfenidone and nintedanib (see
Supplementary material).
Data were extracted from the studies to facilitate the
assessment of their suitability for comparison of trials within
the NMA. Data were collected on key study characteristics,
including study methods, populations, trial settings, treat-
ments, and outcomes. One of the authors extracted key
study characteristics using a standardized data extraction
form, while another checked each extraction. Any discrepan-
cies were resolved by discussion or with the input of a
third author.
Quality assessment of included trials
Two authors independently evaluated the methodological
quality of the included studies, as well as overall quality of
evidence for each of the five outcomes using the Grading
of Recommendations, Assessment, Development and
Evaluations (GRADE), as summarized below.
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Study quality
The quality of the studies was assessed using the Cochrane
risk of bias tool, and two authors independently assessed the
following risk of bias criteria for each included trial: random
sequence generation, allocation concealment, presence of
blinding (participants, personnel, and outcome assessors) in
the studies, incomplete outcome data, and selective outcome
reporting22.
The risk of bias was assessed as recommended: low risk,
high risk, or unclear risk (i.e. either lack of information or
uncertainty over the potential for bias). Disagreements were
resolved by discussion between the authors22.
Overall quality of evidence
The GRADE approach specific to NMA (for each of the five
outcomes) served to assess the quality of the evidence asso-
ciated with specific comparisons, including direct, indirect,
and final network meta-analysis estimates23,24.
Incoherence assessment was not needed in this analysis
as all estimates included only direct (interventions vs pla-
cebo) or only indirect evidence (for all other comparisons).
Data synthesis
Meta-analysis and network meta-analysis methods
Instances of heterogeneity in the study characteristics or out-
come measures were highlighted, and a clinical perspective
was obtained on whether the differences between studies
warranted their exclusion from the analysis. In addition to
this qualitative assessment of heterogeneity in the study
characteristics and outcome measures, a quantitative assess-
ment of heterogeneity was also undertaken to evaluate the
variability in results from study to study. Heterogeneity in
treatment effects was evaluated by estimating the variance
between studies, and through Cochrane Q-test and I2 25,26
when at least two studies were available for each pairwise
comparison. I-squared values of 25%, 50%, and 75% were
defined as low, moderate, and high heterogeneity,
respectively.
Random effects pairwise meta-analyses were conducted
for every treatment comparison, with at least two studies
using ADDIS27. The network meta-analysis model was imple-
mented in the Bayesian framework and estimated using
Markov Chain Monte Carlo (MCMC) methods using ADDIS27.
This approach is recommended by the National Institute for
Health and Clinical Excellence (NICE) Decision support unit
technical support documents on evidence synthesis28.
The odds ratios (OR) for FVC> 10% decrease, acute exac-
erbations, dropouts, serious adverse events, mortality, and
their corresponding 95% confidence intervals (CI), which are
the Bayesian analog of the 95% confidence intervals
are reported29.
The number needed to treat was estimated for an add-
itional beneficial or harmful outcome, with 95% CIs, by using
the derived OR comparing treatment to control and consid-
ering the overall event rate in the comparator group as a
proxy for the community baseline event rate. This method
enabled direct translation into clinical practice30, using
VisualRx with overall (pooled) number of responders within
the available studies as a proxy for the expected rate of res-
ponders in a given IPF population31 (Computer program
www.nntonline.net/visualrx/).
Vague (non-informative) priors were used for model
parameters, and model convergence was assessed by using
the Brooks-Gelman-Rubin diagnostic32.
The model fit was assessed. Goodness-of-fit was evaluated
using the mean residual deviance33 and the rank probabil-
ities produced by the Bayesian analysis (probability of each
treatment to obtain each possible rank in terms of their out-
come values).
Results
The search strategy identified 7,358 records that were
screened and 211 of them were assessed for eligibility. Two
reviewers checked for presence of duplicates, non-RCTs, dis-
ease of interest assessed in the study, outcomes, and inter-
ventions of interest examined. The PRISMA flow chart for
study selection is shown in Figure 134.
Ten trials (eight citations)13,14,35–40 were identified for con-
sideration within the NMA. Four trials compared nintedanib
with placebo and six trials compared pirfenidone with pla-
cebo. These were RCTs that examined the effectiveness and
safety of the treatments and reported the primary and sec-
ondary outcomes of interest. The data collected from the tri-
als can be seen in the table of characteristics (see
Supplementary material).
A pragmatic approach was taken for the NMA in that all
trials were included, regardless of differences in baseline
characteristics, dosing, discontinuation rates, lost to follow-
up, and how missing data were handled.
Networks were developed for change in FVC (decline in
percentage predicted FVC of 10%), for acute exacerbations,
mortality, dropouts, and serious adverse events.
Synthesis of the results
The results of the assessments of heterogeneity and the prin-
cipal NMAs are summarized in Table 1. Regarding FVC
decline 10% both treatments were superior to placebo,
with the results characterized by high, moderate heterogen-
eity, and statistical significance (pirf. vs placebo OR¼ 0.54
(95% CI¼ 0.37–0.80), I2¼ 53% and nint. vs placebo OR¼ 0.59
(95% CI¼ 0.41–0.84), I2¼ 48%). A notable difference was not
found through the indirect comparison (pirf. vs nint.
OR¼ 0.91 (95% CI¼ 0.45–2.03)). Acute exacerbations were
another outcome where the therapies were effective (pirf. vs
placebo OR¼ 0.77 (0.26–2.28) and nint. vs placebo OR¼ 0.61
(0.20–1.90)). Network results showed that pirfenidone was
superior, but the difference was not statistically significant
(pirf. vs nint. OR¼ 0.39 (0.00–15.53)). Dropouts were more
prevalent in the treatments (pirf. vs placebo OR¼ 1.27
(0.96–1.68) and nint. vs placebo OR¼ 1.61 (1.13–2.28)).
Pirfenidone exhibited less frequent discontinuations (pirf.
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vs nint. OR¼ 0.75 (0.33–1.27), and the difference was statis-
tically significant.
An assessment of inconsistency was not required because
none of the networks included any comparisons that were
produced by both direct and indirect evidence.
The risk of bias of each study is presented Figure 2. The
risk of bias analysis indicated that only the Taniguchi et al.36
study was affected by high levels of bias. Bias was detected
in the random sequence generation method used, allocation
concealment, binding of participants, personnel, and
outcome assessment. Certain types of bias could not be
adequately determined in the published studies. Those
included the Ogura et al.39 and Huang et al.40 studies, where
we could only detect the lack of bias in random sequence
generation. Incomplete outcome reporting was noted for the
Azuma et al.35 study. The other studies all lacked any pres-
ence of bias, while the CAPACITY trials14 had an undeter-
mined outcome assessment bias.
When a significant Odds Ratio was calculated for the pri-
mary outcomes of decline in percent predicted FVC 10%
and dropouts, we calculated an NNT (benefit or harm) for
the different levels of risk as represented by control group
event rates over a specified time period using the pooled
Odds Ratio and its confidence interval (Visual Rx). The ana-
lysis is presented in Table 2. Regarding FVC decline, nine
patients would have to be treated with either of the two
therapies, for a beneficial effect to be present (pirf. vs pla-
cebo NNTB¼ 9 (7–23) and nint. vs placebo NNTB¼ 9 (6–22)).
NNTH for discontinuations showed that 12 patients needed
to be treated with pirfenidone for the harmful effect to show
up, in comparison to 14 patients treated with nintedanib.
Regarding the other outcomes nintedanib had better values
(smaller NNTBs and higher NNTHs), with the exception of
acute exacerbations.
Discussion
The present network meta-analysis highlights potentially
important differences between the two newest treatments
for IPF, pirfenidone and nintetanib, compared to placebo
with respect to the decline in percent predicted FVC 10%,
acute exacerbations and mortality. No significant differences
were noted when comparing these two treatments to each
other apart from dropouts. The number needed to treat was
estimated to be the same (NNTB¼ 9) for both treatments
with regards to FVC decline.
The findings of the direct comparison showed that both
drugs were superior to placebo. Other reviews have had
similar results15–19.
The results of the Network meta-analysis showed less
acute exacerbations with pirfenidone compared with ninte-
danib, but the difference was not statistically significant and
was characterized by high heterogeneity. Rinciog et al.19 esti-
mated acute exacerbations at 0.56 (95% CI¼ 0.35–0.89) for
nintedanib and 1.10 (95% CI¼ 0.43–2.85) for pirfenidone,
indicating predominance of pirfenidone. It is worth noting
that the researchers did not include the study of Ogura
et al.39 for nintedanib or the studies of Azuma et al.35,
Huang et al.40, King37, or Taniguchi et al.36 for pirfenidone.
The NMA showed that placebo resulted in fewer drop-
outs. Pirfenidone caused fewer dropouts compared to ninte-
danib [OR¼ 0.75 (0.33–1.27)], the difference was statistically
significant and with little heterogeneity. It is noteworthy that
the profile of adverse events of the two treatments is similar,
however treatment with nintedanib seems to cause more
discontinuations. In terms of safety, these results indicate
that pirfenidone may be a more stable option.
Figure 1. Flow chart of search results.
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With regards to mortality the NMA did not show a differ-
ence between the two drugs [OR¼ 0.93 (0.38–1.94)], with
the results being statistically significant and with little het-
erogeneity. Canestaro et al.17 estimated an OR (95% CI) of
0.87 (0.48–1.66) for pirfenidone vs nintedanib, which con-
firms our results. Loveman et al.18 estimated an OR (95%
CI)¼ 1.39 (0.70–2.82) for nintedanib vs pirfenidone.
With regards to the decline in FVC, there was no differ-
ence between the two drugs, OR (95% CI)¼ 0.91 (0.45–2.03).
Fleetwood et al.15 reported results similar to those of the
present study, OR (95% CI)¼ 0.90 (0.50–1.66) pirfenidone vs
nintedanib, while Loveman et al.18 estimated an OR (95%) of
0.67 (0.51–0.88).
For the serious adverse events (SAEs), there was no differ-
ence between the drugs (OR¼ 1.02, 95% CI¼ 0.62–1.62).
Rochwerg et al.15 reported similar results (OR¼ 1.04,
95%¼ 0.51–2.24). Yoon et al.41 reported on the safety of nin-
tedanib in patients with advanced IPF. They found that
62.7% of the patients with advanced IPF and 47.4% of those
with non-advanced IPF suffered from SAEs. The advanced IPF
group also had more dropouts due to adverse events (68%
vs 40% in the non-advanced group).
Flaherty et al.42 examined the tolerability of pirfenidone-
nintedanib combination therapy, assessing the occurrence of
treatment-emergent adverse events (TEAEs). Of the 89
patients, 78% completed the 24week single-arm, open label
study, with the profile and rate of TEAEs proportionally simi-
lar to that of monotherapies. The researchers reported that
nintedanib was linked to a higher rate of discontinuation
due to TEAEs (10/89) compared to pirfenidone (0/89), but
commented that this may be influenced by the fact that the
included patients were already tolerable to pirfenidone.
Additionally, they note that, due to the similar adverse event
profile of the two therapies, there was uncertainty in identi-
fying the treatment responsible for some of the TEAEs.
Vancheri et al.43 also reported on the safety of combination
Table 1. Synthesis of the results and network quality assessment.
Outcome Measure Model type Pirfenidone vs
Placebo, estimate
(95% CI)
Nintedanib vs Placebo,
estimate (95% CI)
Pirfenidone vs
Nintedanib, estimate
(95% CI)
Mean
residual deviance
Decline in percent pre-
dicted FVC  10%
OR Random effect 0.54 (0.37–0.80)
I2 ¼ 53%
0.59 (0.41–0.84)
I2 ¼ 48%
0.91 (0.45–2.03) 12.17
Low quality (OO)a,b
Acute exacerbations OR Random effect 0.77 (0.26–2.28) 0.61 (0.20–1.90)
I2 ¼ 77%
0.39 (0.00–15.53) 11.57
(OO)a,b
Mortality OR Random effect 0.68 (0.46–1.03)
I2 ¼ 0%
0.70 (0.45–1.09)
I2 ¼ 0%
0.93 (0.38–1.94) 14.76
(OO)b,c
Dropouts OR Random effect 1.27 (0.96–1.68)
I2 ¼ 0%
1.61 (1.13–2.28)
I2 ¼ 17%
0.75 (0.33–1.27) 24.11
Low quality (OO)a,b
Serious adverse events OR Random effect 1.00 (0.78–1.29)
I2 ¼ 0%
0.99 (0.78–1.28)
I2 ¼ 0%
1.02 (0.62–1.62) 11.51
Moderate qual-
ity (O)b
aInconsistency;
bImprecision;
cPoor quality of direct evidence.
 indicator of quality; high (4/4) ,moderate (3/4) ,low (2/4) ,very low (1/4)
Figure 2. Risk of bias of individual studies.
Table 2. Results of NNTB/NNTH estimation.
NNTB or NNTH Pirfenidone vs Placebo Nintedanib vs Placebo
Decline in percent predicted FVC 10% NNTB NNTB 9 (NNTB 7 to NNTB 22) NNTB 9 (NNTB 6 to NNTB 23)
Dropouts NNTH NNTH 12 (NNTH 7 to NNTH 58) NNTH 14 (NNTH 8 to NNTH 61)
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therapy, and found that gastrointestinal adverse events
occurred in 69.8% of patients treated with nintedanib with
add-on pirfenidone and 52.9% of patients treated
with nintedanib.
Crestani et al.44 examined the long-term safety of ninteda-
nib. In a placebo-controlled, open label, extension of the
INPULSIS trials they found that diarrhea was the most com-
mon adverse event, with 15% of the patients discontinuing
because of it. Progression of disease was the most common
reason of discontinuation (26% of patients). In general, the
rates of adverse events were maintained in the long-term
study, and the researchers argue that the results prove the
safety of nintedanib as a solution to the management of dis-
ease progression after initial treatment.
NNTH-NNTB indicated that nintedanib was better than pir-
fenidone in every outcome apart from acute exacerbations
and FVC decline where there was no difference. NNT values
have not been presented previously on these particular
therapies for IPF, and they show that a different clinical inter-
pretation of the outcomes may lead to the conclusion that
nintedanib has an advantage over pirfenidone. Clinical pro-
fessionals can study these statistics and assess how their
own practice will affect their patients.
The quality assessment analysis showed that the results of
the pairwise analysis were characterized by sufficient quality,
with the exception of Nintedanib vs Placebo for acute
exacerbations.
The results of the risk of bias analysis showed low risk for
all clinical studies apart from the Taniguchi et al.36 study.
The strengths of this systematic review and NMA include
the selection of those outcomes (clinically important decline
in FVC, mortality, acute exacerbations, serious adverse
events, and dropouts) that are important in policy decision-
making. FVC decline 10% and acute exacerbations, in par-
ticular, have not been examined thoroughly in recent stud-
ies. Additionally, the calculation of NNT adds to its value as a
study that can inform clinical practitioners. NNTB/NNTH is a
measure of clinical effectiveness that has not been presented
previously in other studies. Finally, the inclusion of all the
most recent RCTs on the examined therapies for IPF makes
the present study unique. This study uses all the eligible
available information and focuses on the two best thera-
peutic options for IPF, thus providing a complete set of data
regarding the effectiveness of nintedanib and pirfenidone.
The limitations of our review include the small number of
studies included, resulting in low certainty in estimates for
the comparisons. Additionally, there were no head-to-head
trials between nintetanib and pirfenidone to compare the
result of the indirect comparison.
Conclusion
In conclusion, the results of the NMA suggest that both pirfe-
nidone and nintedanib are superior to placebo, but that they
do not demonstrate a clear case of dominance of one over
the other. The difference in the occurrence of dropouts indi-
cates a slight clinical advantage of pirfenidone when it
comes to safety, and this may be of interest when choosing
an appropriate long-term solution for IPF, while the NNTB/
NNTH results favor nintedanib as a treatment option. These
results show the presence of marginal differences between
the two therapies, and a comparison of the costs for the two
therapies may be able to compliment the process of making
a cost-effective decision with respect to IPF therapy.
Key points
 Review of all the RCTs on the therapy of IPF with pirfeni-
done and nintedanib up to September 2017.
 Use of NNTB and NNTH to estimate the therapeutic
impact and provide a statistical figure, more meaningful
to a health professional.
 Indirect comparison of the two treatments indicated a
decreased dropout rate associated with pirfenidone, while
the number needed to treat was smaller in the case of
nintedanib, suggesting a better overall clinical
effectiveness.
 Proof that an economic comparison may be useful to the
decision-making process regarding the reimbursement of
therapy for IPF.
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